Pillsbury: Biotech Company Vasa Therapeutics Secures $6M in Seed Funding Round
January 05, 2024
January 05, 2024
NEW YORK, Jan. 5 -- Pillsbury, a law firm, issued the following news release:
Pillsbury advised Vasa Therapeutics, Inc., a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, in a recent $6 million seed funding round led by Orphinic Scientific SA.
Private investments funds including NuFund Venture Group, SeedFolio, among others, also participated. Of the $6 million biotech investment, $2.3 million was supplemented by non-dilu . . .
Pillsbury advised Vasa Therapeutics, Inc., a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, in a recent $6 million seed funding round led by Orphinic Scientific SA.
Private investments funds including NuFund Venture Group, SeedFolio, among others, also participated. Of the $6 million biotech investment, $2.3 million was supplemented by non-dilu . . .